C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects

被引:67
作者
Min, DI [1 ]
Ellingrod, VL [1 ]
机构
[1] Univ Iowa, Coll Pharm, Div Clin & Adm Pharm, Iowa City, IA 52242 USA
关键词
MDR1 gene mutation; P-glycoprotein; cyclosporine; pharmacokinetics;
D O I
10.1097/00007691-200206000-00012
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
To determine the relationship between C3435T mutation in exon 26 of the human multidrug resistant 1 (MDR1) gene and cyclosporine pharmacokinetic parameters among healthy volunteers, the oral cyclosporine pharmacokinetic study was performed for 14 healthy subjects, Blood cyclosporine concentrations were measured by HPLC. Concentration-time data were analyzed by a noncompartmental method using WinNonLin, and the blood samples were genotyped for the C3435T polymorphism of MDR1 gene using the PCR and a restriction digest. Each cyclosporine pharmacokinetic parameter was compared using the Mann-Whitney U test according to his or her P-gp genotype. There were seven (7) homozygous Cl, six (6) C/T, and one (1) homozygous T/T genotypes in these 14 healthy volunteers. According to their genotypes, mean t(max) 1.6+/-0.3 hours, mean C-max 1337+/-329 ng/mL, mean Cl/F 66.5+/-18.3 L/h, and mean AUC 5642+/-1577 ng.h/mL in C1/F group and mean t(max) 2.0+/-0.6 hours, mean C-max 1540+/-721 ng/mL, mean Cl/F 55.2+/-18.9 L/h, and mean AUC 6902+/-1405 ng.h/mL in C/T+T/T group. Although C-max and AUC in C/T and T/T group were 15% and 227c larger than those in C/C group, none of these parameter comparisons was statistically significant. There were no statistical differences in cyclosporine pharmacokinetics among different MDR1 genotypes in these 14 healthy subjects.
引用
收藏
页码:400 / 404
页数:5
相关论文
共 25 条
[11]   DEMOGRAPHIC-FACTORS INFLUENCING CYCLOSPORINE PHARMACOKINETIC PARAMETERS IN PATIENTS WITH UREMIA - RACIAL-DIFFERENCES IN BIOAVAILABILITY [J].
LINDHOLM, A ;
WELSH, M ;
ALTON, C ;
KAHAN, BD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (04) :359-371
[12]   FACTORS INFLUENCING THE PHARMACOKINETICS OF CYCLOSPORINE IN MAN [J].
LINDHOLM, A .
THERAPEUTIC DRUG MONITORING, 1991, 13 (06) :465-477
[13]   P-glycoprotein and drug therapy in organ transplantation [J].
Lo, A ;
Burckart, GJ .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (10) :995-1005
[14]   Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine [J].
Lown, KS ;
Mayo, RR ;
Leichtman, AB ;
Hsiao, HL ;
Turgeon, DK ;
SchmiedlinRen, P ;
Brown, MB ;
Guo, WS ;
Rossi, SJ ;
Benet, LZ ;
Watkins, PB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) :248-260
[15]   Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient [J].
Masuda, S ;
Uemoto, S ;
Hashida, T ;
Inomata, Y ;
Tanaka, K ;
Inui, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (01) :98-+
[16]   Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers [J].
Min, DI ;
Lee, M ;
Ru, YM ;
Flanigan, M .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) :478-486
[17]  
Nauck M, 2000, CLIN CHEM, V46, P1995
[18]  
SAWCHUK RJ, 1981, CLIN CHEM, V27, P1368
[19]  
Schinkel AH, 1998, INT J CLIN PHARM TH, V36, P9
[20]  
Schuetz EG, 2000, MOL PHARMACOL, V57, P188